Breast Cancer Gene Signature Assay

Identifies patients’ 10 years risk of breast cancer recurrence

  • FDA approved; CAP & CLIA accredited test.
  • This gene signature assay is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II) or node-positive (Stage II or III) early-stage breast cancer to be treated with adjuvant endocrine therapy.
  • It is powered by nCounter digital technology.
  • Test used to predict patient’s Risk of Recurrence(ROR).
  • Test included in international clinical practice guidelines.

For more information :

Please refer https://www.oncocyte.com/ or please contact your local sales representative or

Email us at info@sayretherapeutics.com